UK – NICE approves Ofev for PF-ILD

The National Institute for Health and Care Excellence (NICE) has recommended Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of adult patients with chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILD).

The recommendation is supported by data from the Phase III INBUILD trial, which found Ofev met the primary endpoint of significantly slowing disease progression – defined as an absolute decline in forced vital capacity (FVC) over 52 weeks in patients with PF-ILD versus placebo.

“This is a landmark moment for patients with PF-ILD. Action for Pulmonary Fibrosis is delighted that a treatment option is now available for people living with this condition, which can be devastating for the people who live with it daily, as well as their families and carers. This is the news our patient community have been long waiting for,” said Steve Jones, chair of Trustees, Action for Pulmonary Fibrosis…